With the arrival of a new class of single-nucleotide editors, researchers can target the most common type of pathogenic SNP in humans.

Researchers use gold nanoparticles to deliver CRISPR-Cas9 and correct a point mutation in a mouse model of Duchenne muscular dystrophy. 

Six scientists question the authors’ conclusions about the DNA repair process that led to the human embryos’ correction of a defective gene.